CYTOKINE AND ADHESION MOLECULE EXPRESSION IN KAPOSI'S

点击翻译按钮获取中文摘要

We hypothesize that because of infections and immune dysregulation experienced by certain HIV-infected patients, Kaposi's sarcoma (KS) cells and their precursors are exposed to high levels of cytokines and to components of the infectious agents, such as double stranded RNA and lipopolysaccharide. We hypothesize that these agents activate NF-kappa- B-like transcription factors, and that this activation contributes to the induced expression of cellular adhesion molecules (CAMs) on KS cells and their precursors, thereby enhancing adhesion of specific types of leukocytes. These same agents also induce IL-6 expression by KS cells, suggesting that IL-6 expressed by the KS cells might contribute to activation of the adherent leukocytes. We hypothesize that these leukocytes provide factors, including the Tat protein of HIV and additional IL-6 and Oncostatin M, agents that are mediators in the development of KS. Although KS cells in culture maintain a phenotype that is distinct from other cell types that could be considered candidate precursors, neither CAM expression nor IL-6 expression is constitutive in KS cells, suggesting that host factors are responsible for the high levels of expression that occur in KS lesions. Because NF-kappa-B consensus sites exists in the regulatory regions of the CAMs, IL-6 and HIV, the shared molecule event of activation of NF-kappa-B could be necessary for many of the changes that lead to the development and progression of KS, and as such could serve as a target of clinical intervention. We have identified several mechanisms to interfere with NF-kappa-B-driven gene expression by these agents. These experiments are designed to enhance our understanding of the regulation of CAM and IL-6 expression in KS and the functional consequences of their induction by different agents. In addition, we will explore the consequences of targeting NF-gamma-B-like proteins as a shared transcription factor involved in the expression of these genes as a possible therapeutic strategy for the treatment of KS.